E-mail list
Keep up-to-date with the work of the GI with our e-mail bulletin every few weeks.
Six of the best
CIPE Development BlogJohan Norberg
Philippe Legrain
Pienso
World Bank PSD
Trade Diversion
Blogroll
About Globalization
Adam Smith Institute
Atlantic Blog
Brian Micklethwait
Business & Economics
Cafe Hayek
Capital Spectator
Catallaxy
Center for Global Development
Chippla's weblog
Civitas Blog
Club for Growth
ConservativeHome
Daniel W. Drezner
David Smith
De Gustibus
EconLog
Franck's blog
Freedom Institute (Ireland)
From the Heartland
Gavin Sheridan
Global Growth Blog
Hillary Johnson
Hit and Run
Iain Dale
IndiaUncut
Institutional Economics
Knowledge Problem
Kurt Johnson
Market Center Blog
Mises Institute
Mutualist Blog
Natalie Solent
ODI
Owen Barder
Pharmopoly
Positive Externality
Private Sector Development
Radley Balko
Right to Create
Rip Mix Burn
Samizdata.net
Sobering thoughts
Social Affairs Unit
Spontaneous Order
TechDirt
The American Mind
The Commons Blog
The Liberal Order
The Welfare State We're In
Tim Worstall
Tom G. Palmer
Trade Diversion
Unrestricted Domain
Vaccines for Development
| Debating drug spending |
|
|
|
| Monday, 07 March 2005 | |
|
I had a letter in Saturday's Washington Times: Doug Bandow rightly points out that the price of drugs is not the highest factor in the cost of U.S. health care ("The costs of health care" Op-Ed, Wednesday). Nevertheless, drug companies benefit, at the expense of patients, from the lack of free trade in pharmaceuticals. The ban on drug reimportation helps drug companies enjoy the highest profit margins of any U.S. industry, almost four times the Fortune 500 average. Removing the ban on drug reimportation will cut costs for American consumers without harming research and development. |